UK MHRA Green Lights AbbVie’s ELAHERE for Ovarian Cancer

UK MHRA green lights AbbVie’s ELAHERE for ovarian cancer

AbbVie has secured UK marketing authorisation for ELAHERE (mirvetuximab soravtansine), the first antibody-drug conjugate (ADC) approved in the country for treating folate receptor-alpha (FRα) high, platinum-resistant ovarian cancer.

Mirvetuximab Soravtansine Receives Conditional Marketing Authorization in GYN Subtypes

Patients with FRα+, platinum-resistant high-grade serous epithelial ovarian, fallopian tube, or primary peritoneal cancer may now be eligible for mirvetuximab soravtansine in the UK.

AbbVie’s First in Class Therapy ELAHERE® ▼ (mirvetuximab soravtansine) Licensed by the Medicines and Healthcare products Regulatory Agency for the Treatment of Eligible Adult Patients with Platinum-Resistant Ovarian Cancer - Oncology Today

AbbVie has announced it has received marketing authorisation from the UK Medicines and Healthcare products Regulatory Agency (MHRA) for ELAHERE® (mirvetuximab soravtansine) as monotherapy for the treatment of eligible adult patients with folate receptor-alpha (FRα) positive, platinum-resistant high-grade serous epithelial ovarian, fallopian tube, or primary peritoneal cancer who have received one to three prior systemic treatment regimens.